



### A PIONEER DIAGNOSTIC CENTRE

NAME : Mrs. PARAMJEET KAUR

AGE/ GENDER : 53 YRS/FEMALE **PATIENT ID** : 1639618

**COLLECTED BY** REG. NO./LAB NO. : 122410100003

REFERRED BY **REGISTRATION DATE** : 10/Oct/2024 09:03 AM BARCODE NO. : 12505123 **COLLECTION DATE** : 10/Oct/2024 09:09AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 10/Oct/2024 05:24PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval** 

### **HAEMATOLOGY**

### **GLYCOSYLATED HAEMOGLOBIN (HBA1C)**

GLYCOSYLATED HAEMOGLOBIN (HbA1c):  $6.5^{H}$ 4.0 - 6.4WHOLE BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

ESTIMATED AVERAGE PLASMA GLUCOSE 139.85 mg/dL 60.00 - 140.00

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

### **INTERPRETATION:**

AS PER AMERICAN DIABETES ASSOCIATION (ADA):				
REFERENCE GROUP	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %			
Non diabetic Adults >= 18 years	<5.7			
At Risk (Prediabetes)	5.7 – 6.4			
Diagnosing Diabetes	>= 6.5			
	Age > 19 Years			
	Goals of Therapy:	< 7.0		
Therapeutic goals for glycemic control	Actions Suggested:	>8.0		
	Age < 19 Years			
	Goal of therapy:	<7.5		

### COMMENTS:

- 1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with the rapeutic regimen in diabetic patients.
- 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate.
- HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications
- 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.
- 6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.
- 7. Specimens from patients with polycythemia or post-spienctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mrs. PARAMJEET KAUR

**AGE/ GENDER** : 53 YRS/FEMALE **PATIENT ID** : 1639618

**COLLECTED BY** REG. NO./LAB NO. : 122410100003

REFERRED BY **REGISTRATION DATE** : 10/Oct/2024 09:03 AM BARCODE NO. : 12505123 **COLLECTION DATE** : 10/Oct/2024 09:09AM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 10/Oct/2024 05:24PM


**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval** 

### LIFOTRONIC Graph Report

Name :	Case:	Patient Type :	Test Date: 10/10/2024 15:36:18
Age:	Department:	Sample Type: Whole Blood EDTA	Sample ld: 12505123
Gender:			Total Area: 13273

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	69	4166	11934	86.4
HbA1c	38	82	716	6.5
La1c	25	43	267	1.9
HbF	20	12	63	0.4
Hba1b	13	66	208	1.5
Hba1a	11	29	85	0.6





CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. PARAMJEET KAUR

AGE/ GENDER : 53 YRS/FEMALE **PATIENT ID** : 1639618

**COLLECTED BY** REG. NO./LAB NO. : 122410100003

REFERRED BY **REGISTRATION DATE** : 10/Oct/2024 09:03 AM BARCODE NO. : 12505123 **COLLECTION DATE** : 10/Oct/2024 09:09AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 10/Oct/2024 11:36AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval** Test Name

### CLINICAL CHEMISTRY/BIOCHEMISTRY **GLUCOSE FASTING (F)**

**GLUCOSE FASTING (F): PLASMA** 105.03<sup>H</sup> mg/dL NORMAL: < 100.0

by GLUCOSE OXIDASE - PEROXIDASE (GOD-POD) PREDIABETIC: 100.0 - 125.0 **DIABETIC:** > **0R** = **126.0** 

IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

1. A fasting plasma glucose level below 100 mg/dl is considered normal.

2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.

3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



CLIENT CODE.



### PKR JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

REPORTING DATE

: 10/Oct/2024 11:36AM

**NAME** : Mrs. PARAMJEET KAUR

**AGE/ GENDER** : 53 YRS/FEMALE **PATIENT ID** : 1639618

**COLLECTED BY** REG. NO./LAB NO. : 122410100003

REFERRED BY **REGISTRATION DATE** : 10/Oct/2024 09:03 AM BARCODE NO. : 12505123 **COLLECTION DATE** : 10/Oct/2024 09:09AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name	Value	Unit	Biological Reference interval
	LIPID PROFILE	: BASIC	
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP	139.96	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)	235.6 <sup>H</sup>	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION	34.22	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	58.62	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	105.74	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	47.12 <sup>H</sup>	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM  by CALCULATED, SPECTROPHOTOMETRY	515.52	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	4.09	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.71	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. PARAMJEET KAUR

AGE/ GENDER : 53 YRS/FEMALE **PATIENT ID** : 1639618

**COLLECTED BY** REG. NO./LAB NO. : 122410100003

REFERRED BY **REGISTRATION DATE** : 10/Oct/2024 09:03 AM BARCODE NO. **COLLECTION DATE** : 10/Oct/2024 09:09AM : 12505123 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 10/Oct/2024 11:36AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval** 

TRIGLYCERIDES/HDL RATIO: SERUM 6.88<sup>H</sup> RATIO 3.00 - 5.00

by CALCULATED, SPECTROPHOTOMETRY INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)